HMPL-A830 in Solid Tumors

StatusRecruiting
PhasePhase 1/2
SponsorHutchmed
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 10 months later Jun 26, 2028 → May 23, 2029
See other at-risk trials from Hutchmed

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jun 26, 2028 to May 23, 2029 Show 5 more changesShow less
    • Recruitment opened
    • Trial sites expanded: 7 → 14 locations
    • Study completion pushed from Nov 26, 2028 to Dec 15, 2029
    • Start date changed from estimate of Aug 15, 2026 to Sep 24, 2026
    • Eligibility criteria expanded, about 12 words
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Hutchmed
23 trials monitored
See 1 trial at risk
This is a first-in-human (FIH), multicenter, open-label, phase I/Ⅱa clinical study of HMPL-A830 in participants with histologically or cytologically confirmed, unresectable, advanced, or metastatic solid tumors\*, who are refractory or progressed on/after available standard treatment. The study will be conducted in 2 parts: Dose Escalation (Part A, Phase I), approximately 57 participants will be enrolled. Dose Optimization (Part B, Phase IIa), approximately 90 participants will be enrolled.
Trial Details
NCT Number NCT07718581
Lead Sponsor Hutchmed
Conditions
(from sponsor)		 Solid Tumor, Adult
Enrollment 147 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov